Alto Neuroscience ANRO Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement
Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's costs from sale of common stock and pre-funded warrants in private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's costs from sale of common stock and pre-funded warrants in private placement?
- Alto Neuroscience (ANRO) reported costs from sale of common stock and pre-funded warrants in private placement of $4.88M in Q1 2026.
- What does costs from sale of common stock and pre-funded warrants in private placement mean?
- Includes direct costs incurred in connection with equity financing activities, such as underwriting fees, legal expenses, and registration costs. Tracking these costs is vital for assessing the efficiency of capital raising efforts and the net proceeds retained by the company. High costs relative to proceeds may indicate unfavorable financing terms or complex deal structures.